Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes

INTRODUCTION: To examine the utility of sequential versus dual add-on approaches in patients who have type 2 diabetes and inadequate glycemic control with metformin therapy alone, we characterized the efficacy and safety of dual therapy with dapagliflozin or saxagliptin added to metformin in the ope...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Ther
Hlavní autoři: Mathieu, Chantal, Catrinoiu, Doina, Ranetti, Aurelian Emil, Johnsson, Eva, Hansen, Lars, Chen, Hungta, Garcia-Sanchez, Ricardo, Iqbal, Nayyar, Celiñski, Aleksander
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2018
Témata:
Brief Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6064585/
https://ncbi.nlm.nih.gov/pubmed/29802530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-018-0445-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky